美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床效果观察

Observation on clinical effect of metoprolol combined with trimetazidine in the treatment of coronary heart disease and heart failure

目的分析研究美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床效果。方法92例冠心病心力衰竭患者,随机分为对照组和观察组,每组46例。对照组患者服用美托洛尔,观察组在对照组的基础上同时服用曲美他嗪。比较两组患者临床疗效、心电图改善情况以及治疗前后左室射血分数、收缩压(SBP)、舒张压(DBP)、心率(HR)水平。结果观察组治疗总有效率95.65%高于对照组的80.43%,差异具有统计学意义(P<0.05);观察组治疗后左室射血分数(52.1±6.8)%高于对照组的(44.6±7.4)%,差异具有统计学意义(P<0.05);观察组患者心电图改善总有效率93.48%高于对照组的73.91%,差异均具有统计学意义(P<0.05)。治疗后,观察组患者SBP、DBP、HR水平分别为(105.82±7.34)mm Hg(1 mm Hg=0.133 kPa)、(71.54±7.41)mm Hg、(72.98±6.83)次/min,均低于对照组的(123.85±9.43)mm Hg、(85.65±8.94)mm Hg、(84.85±7.19)次/min,差异均具有统计学意义(P<0.05)。结论冠心病心力衰竭患者采用美托洛尔联合曲美他嗪治疗的临床治疗效果显著,心电图与临床病症均得到有效改善,减少患者心肌细胞中的有毒物质,降低患者致残率和致死率,提高患者生命质量,值得临床推广应用。

Objective To analyze the clinical effect of metoprolol combined with trimetazidine in the treatment of coronary heart disease and heart failure.Methods A total of 92 patients with coronary heart disease and heart failure were randomly divided into control group and observation group,with 46 cases in each group.The control group was treated by metoprolol,and the observation group was treated by trimetazidine on the basis of the control group.The clinical efficacy,improvement of electrocardiogram,left ventricular ejection fraction,systolic blood pressure(SBP),diastolic blood pressure(DBP),heart rate(HR)levels before and after treatment were compared between the two groups.Results The total effective rate of treatment 95.65%of the observation group was higher than that of the control group 80.43%,and the difference was statistically significant(P<0.05).The left ventricular ejection fraction(52.1±6.8)%of the observation group was higher than that of the control group(44.6±7.4)%,and the difference was statistically significant(P<0.05).The total effective rate of electrocardiogram improvement 93.48%of the observation group was higher than that of the control group 73.91%,and the difference was statistically significant(P<0.05).After treatment,the levels of SBP,DBP and HR of the observation group were(105.82±7.34)mm Hg(1 mm Hg=0.133 kPa),(71.54±7.41)mm Hg and(72.98±6.83)times/min,which were all lower than those of the control group(123.85±9.43)mm Hg,(85.65±8.94)mm Hg and(84.85±7.19)times/min,and the difference was statistically sigificant(P<0.05).Conclusion Metoprolol combined with trimetazidine shows remarkable clinical effect for coronary heart disease and heart failure,which can effectively improve the eelectrocardiogram and clinical symptoms,reduce toxic substances in myocardial cells,reducing disability and mortality,and improving quality of life of patients.It is worthy of clinical promotion and application.